Logo image of ACIU

AC IMMUNE SA (ACIU) Stock Fundamental Analysis

NASDAQ:ACIU - Nasdaq - CH0329023102 - Common Stock - Currency: USD

1.685  -0.01 (-0.88%)

Fundamental Rating

3

Taking everything into account, ACIU scores 3 out of 10 in our fundamental rating. ACIU was compared to 560 industry peers in the Biotechnology industry. The financial health of ACIU is average, but there are quite some concerns on its profitability. ACIU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACIU has reported negative net income.
In the past year ACIU had a positive cash flow from operations.
ACIU had negative earnings in each of the past 5 years.
ACIU had negative operating cash flow in 4 of the past 5 years.
ACIU Yearly Net Income VS EBIT VS OCF VS FCFACIU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

ACIU's Return On Assets of -24.67% is fine compared to the rest of the industry. ACIU outperforms 72.14% of its industry peers.
ACIU has a better Return On Equity (-54.94%) than 61.79% of its industry peers.
Industry RankSector Rank
ROA -24.67%
ROE -54.94%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ACIU Yearly ROA, ROE, ROICACIU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

ACIU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACIU Yearly Profit, Operating, Gross MarginsACIU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

ACIU does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACIU has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ACIU has more shares outstanding
Compared to 1 year ago, ACIU has a worse debt to assets ratio.
ACIU Yearly Shares OutstandingACIU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACIU Yearly Total Debt VS Total AssetsACIU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.21, we must say that ACIU is in the distress zone and has some risk of bankruptcy.
ACIU has a Altman-Z score (-2.21) which is in line with its industry peers.
ACIU has a debt to FCF ratio of 0.11. This is a very positive value and a sign of high solvency as it would only need 0.11 years to pay back of all of its debts.
The Debt to FCF ratio of ACIU (0.11) is better than 97.14% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that ACIU is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.04, ACIU is not doing good in the industry: 61.43% of the companies in the same industry are doing better.
Although ACIU does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.11
Altman-Z -2.21
ROIC/WACCN/A
WACC4.88%
ACIU Yearly LT Debt VS Equity VS FCFACIU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ACIU has a Current Ratio of 1.53. This is a normal value and indicates that ACIU is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.53, ACIU is doing worse than 81.61% of the companies in the same industry.
A Quick Ratio of 1.53 indicates that ACIU should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.53, ACIU is not doing good in the industry: 81.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.53
ACIU Yearly Current Assets VS Current LiabilitesACIU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.11% over the past year.
Looking at the last year, ACIU shows a very strong growth in Revenue. The Revenue has grown by 91.20%.
The Revenue for ACIU have been decreasing by -24.39% on average. This is quite bad
EPS 1Y (TTM)13.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
Revenue 1Y (TTM)91.2%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%N/A

3.2 Future

ACIU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.45% yearly.
The Revenue is expected to grow by 57.79% on average over the next years. This is a very strong growth
EPS Next Y-57.47%
EPS Next 2Y-10.47%
EPS Next 3Y29.97%
EPS Next 5Y39.45%
Revenue Next Year-87.63%
Revenue Next 2Y-8.46%
Revenue Next 3Y55.88%
Revenue Next 5Y57.79%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ACIU Yearly Revenue VS EstimatesACIU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
ACIU Yearly EPS VS EstimatesACIU Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ACIU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACIU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACIU Price Earnings VS Forward Price EarningsACIU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ACIU is valued cheaply inside the industry as 99.64% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.09
EV/EBITDA N/A
ACIU Per share dataACIU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ACIU's earnings are expected to grow with 29.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.47%
EPS Next 3Y29.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACIU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AC IMMUNE SA

NASDAQ:ACIU (5/30/2025, 1:49:06 PM)

1.685

-0.01 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners28.02%
Inst Owner Change-5.42%
Ins Owners3.06%
Ins Owner ChangeN/A
Market Cap169.19M
Analysts88
Price Target9.18 (444.81%)
Short Float %2.21%
Short Ratio7.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.71%
Min EPS beat(2)9.14%
Max EPS beat(2)16.28%
EPS beat(4)3
Avg EPS beat(4)-8.33%
Min EPS beat(4)-183.77%
Max EPS beat(4)125.04%
EPS beat(8)5
Avg EPS beat(8)-99.25%
EPS beat(12)9
Avg EPS beat(12)-61.26%
EPS beat(16)10
Avg EPS beat(16)-68.13%
Revenue beat(2)2
Avg Revenue beat(2)125.27%
Min Revenue beat(2)50.21%
Max Revenue beat(2)200.32%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10%
PT rev (3m)-10%
EPS NQ rev (1m)7.2%
EPS NQ rev (3m)-11.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-219.14%
Revenue NQ rev (1m)-0.49%
Revenue NQ rev (3m)-20.78%
Revenue NY rev (1m)11.04%
Revenue NY rev (3m)-94.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.95
P/FCF 3.09
P/OCF 3.04
P/B 1.48
P/tB 3.16
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)0.55
FCFY32.35%
OCF(TTM)0.55
OCFY32.84%
SpS0.34
BVpS1.14
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.67%
ROE -54.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 160.12%
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.11
Debt/EBITDA N/A
Cap/Depr 31.06%
Cap/Sales 2.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.53
Altman-Z -2.21
F-Score5
WACC4.88%
ROIC/WACCN/A
Cap/Depr(3y)38.45%
Cap/Depr(5y)62.34%
Cap/Sales(3y)13.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
EPS Next Y-57.47%
EPS Next 2Y-10.47%
EPS Next 3Y29.97%
EPS Next 5Y39.45%
Revenue 1Y (TTM)91.2%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%N/A
Revenue Next Year-87.63%
Revenue Next 2Y-8.46%
Revenue Next 3Y55.88%
Revenue Next 5Y57.79%
EBIT growth 1Y7.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.67%
EBIT Next 3Y-16.92%
EBIT Next 5Y-11.51%
FCF growth 1Y166.51%
FCF growth 3YN/A
FCF growth 5Y4.12%
OCF growth 1Y168.43%
OCF growth 3YN/A
OCF growth 5Y3.58%